• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Stereotaxis wins FDA clearance for Synchrony cath lab tech

Stereotaxis wins FDA clearance for Synchrony cath lab tech

April 6, 2026 By Sean Whooley

Stereotaxis Synchrony screen
The Synchrony system [Image from Stereotaxis]
Stereotaxis (NYSE:STXS) announced today that it received FDA 510(k) clearance for its Synchrony system.

The St. Louis-based developer of surgical robotic technology for minimally invasive endovascular intervention designed its Synchrony platform to digitize and modernize the interventional cath lab. FDA clearance comes about six months after the company submitted Synchrony to the agency. At that time, it also received CE mark for the technology.

Synchrony features a slim, 55” 4K ultra-high-definition display, consolidating the viewing and control of all disparate systems in the lab. It offers an enhanced procedure experience with custom layouts and streamlined workflows. The system also has an intuitive user interface and a decluttered environment.

Stereotaxis says that Synchrony digitizes video streams with full fidelity and less than a single-frame latency for clear visualization. Its architecture allows obsolescence protection for labs as new technologies roll out in the future.

The company offers Synchrony with SynX, a cloud-based HIPAA and GDPR-compliant app. SynX allows for secure, remote connectivity, collaboration, recording and cath lab monitoring.

Matthew Dare, who serves as research and technology coordinator at Texas Cardiac Arrhythmia Institute in Austin, Texas, says the technology offers a “better intraoperative experience for physicians and nurses.” Dare adds that it offers attractive tools for managing cardiovascular programs with remote monitoring, collaboration and recordings.

With clearance, Stereotaxis reiterates its guidance for more than $3 million in Synchrony revenue in 2026.

David Fischel, Stereotaxis chair and CEO, said:

“Synchrony and SynX are central to our digital surgery efforts to modernize the interventional lab with enhanced workflow, remote connectivity, and smart AI capabilities. The technology improves the robotic cockpit, and will be critical in supporting robotic efforts for remote long-distance procedures and automated catheter navigation. The opportunity is much broader than robotic labs as we believe all cath labs stand to benefit from improved workflow, connectivity, and collaboration.”

Filed Under: Artificial Intelligence (AI), Cardiovascular, Health Technology, Imaging, Machine Learning (ML), Software / IT Tagged With: Stereotaxis

More recent news

  • Medtronic announces a company president
  • Medtronic nets CE mark for Vitalis family of conduction system pacemakers
  • E2’s pulmonary embolism platform claims two FDA clearances
  • Resmed to launch AirTouch F40 full-face fabric CPAP mask in US
  • Paradromics taps Siemens Healthineers to develop scalable BCI imaging

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy